cash flow reconciliationreview2022-11-30
Operating, investing and financing flows differ from the reported change in cash by 11550000, beyond tolerance 1000000.
Revenue
$225.30M
Fiscal year ended 2026-05-31Operating income
$3.10M
Fiscal year ended 2026-05-31Free cash flow
Unavailable
Fiscal year ended 2026-05-31NEOGEN CORP (NEOG) reported revenue of $225.30M and net income of -$11.30M for the fiscal year ended 2026-05-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEOGEN CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.
Income
| Metric | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $225.30M | $211.20M | $224.69M | $209.19M | $225.50M | $221.00M | $231.26M | $216.96M | $236.77M | $228.81M |
| Cost of revenue | $117.50M | $112.20M | $118.01M | $114.22M | $132.60M | $110.70M | $117.93M | $112.04M | $123.29M | $111.93M |
| Gross profit | $107.80M | $99.00M | $106.68M | $94.97M | $92.90M | $110.30M | $113.33M | $104.93M | $113.48M | $116.88M |
| Operating income | $3.10M | -$3.30M | -$5.38M | -$16.09M | -$611.20M | $5.40M | -$457.48M | $2.26M | $12.98M | $12.02M |
| Net income | -$11.30M | -$17.00M | -$15.92M | $36.34M | -$612.20M | -$10.90M | -$456.28M | -$12.61M | -$5.39M | -$2.02M |
| Research & development | $4.90M | $3.80M | $4.56M | $5.12M | $6.30M | $4.50M | $5.11M | $5.20M | $5.17M | $4.85M |
| Weighted-average diluted shares | Unavailable | shares 217.67M | shares 217.41M | shares 217.33M | Unavailable | shares 217.03M | shares 216.81M | shares 216.70M | Unavailable | shares 216.60M |
| Pretax income | -$12.10M | -$20.30M | -$20.36M | $43.81M | -$631.20M | -$9.70M | -$476.57M | -$15.61M | -$6.39M | -$5.82M |
| Income tax expense | -$800.00K | -$3.30M | -$4.44M | $7.47M | -$19.00M | $1.20M | -$20.29M | -$3.00M | -$1.00M | -$3.80M |
| Diluted EPS | Unavailable | $-0.08 | $-0.07 | $0.17 | Unavailable | $-0.05 | $-2.10 | $-0.06 | Unavailable | $-0.01 |
| Selling, general & administrative | $99.80M | $98.50M | $107.50M | $105.94M | $99.90M | $100.40M | $104.32M | $97.47M | $95.34M | $100.01M |
| General & administrative | $58.70M | $60.30M | $65.21M | $60.89M | $53.00M | $55.80M | $57.77M | $51.67M | $50.97M | $52.09M |
| Selling & marketing | $41.10M | $38.20M | $42.29M | $45.05M | $46.90M | $44.60M | $46.54M | $45.80M | $44.36M | $47.92M |
Balance
| Metric | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $185.50M | $159.90M | $145.34M | $138.88M | $129.00M | $127.70M | $140.23M | $120.48M | $170.61M | $161.44M |
| Total assets | $3.35B | $3.36B | $3.36B | $3.38B | $3.44B | $4.04B | $4.05B | $4.50B | $4.55B | $4.58B |
| Current assets | $604.60M | $590.00M | $574.58M | $524.06M | $576.90M | $551.71M | $570.45M | $540.65M | $589.23M | $602.47M |
| Total liabilities | $1.25B | $1.26B | $1.26B | $1.26B | $1.37B | $1.38B | $1.39B | $1.37B | $1.40B | $1.44B |
| Current liabilities | $158.20M | $150.60M | $147.05M | $146.20M | $174.00M | $141.20M | $151.20M | $122.69M | $154.32M | $157.84M |
| Total equity incl. NCI | $2.09B | $2.10B | $2.10B | $2.12B | $2.07B | $2.66B | $2.67B | $3.14B | $3.14B | $3.15B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $144.30M | $161.70M | $162.77M | $193.41M | $190.80M | $205.44M | $198.27M | $198.60M | $189.27M | $182.39M |
| Accounts receivable | $146.80M | $137.10M | $132.00M | $138.46M | $153.40M | $160.07M | $164.09M | $167.64M | $173.00M | $173.59M |
| Goodwill | $1.05B | $1.05B | $1.05B | $1.07B | $1.06B | $1.67B | $1.67B | $2.14B | $2.14B | $2.14B |
| Long-term debt | $793.70M | $793.30M | $792.93M | $792.53M | $874.80M | $890.60M | $889.87M | $889.13M | $888.39M | $887.65M |
| Accounts payable | $79.10M | $75.20M | $63.04M | $76.60M | $79.60M | $72.24M | $79.57M | $61.46M | $83.06M | $89.75M |
Cash flow
| Metric | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $30.20M | $22.70M | $19.44M | $10.85M | $16.40M | $19.46M | $40.25M | -$17.91M | $26.78M | -$30.21M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | -$4.00M | -$11.56M | -$11.67M | $97.72M | -$15.90M | -$32.48M | -$17.16M | -$33.66M | -$17.51M | -$14.64M |
| Financing cash flow | -$300.00K | $744.00K | -$451.00K | -$99.39M | -$2.10M | $930.00K | -$1.41M | $979.00K | -$99.00K | $1.25M |
| Net change in cash | $25.60M | $14.56M | $6.46M | $9.88M | $1.30M | -$12.52M | $19.75M | -$50.13M | $9.20M | -$44.33M |
| Stock-based compensation | $3.00M | $1.10M | $4.34M | $4.96M | $4.30M | $4.20M | $4.82M | $3.98M | $3.97M | $3.68M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $29.40M | $28.92M | $28.93M | $29.06M | $30.30M | $29.35M | $30.05M | $29.80M | $28.85M | $29.65M |
Derived
| Metric | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 47.8% | 46.9% | 47.5% | 45.4% | 41.2% | 49.9% | 49.0% | 48.4% | 47.9% | 51.1% |
| Operating margin | 1.4% | -1.6% | -2.4% | -7.7% | -271.0% | 2.4% | -197.8% | 1.0% | 5.5% | 5.3% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.3% | 0.5% | 1.9% | 2.4% | 1.9% | 1.9% | 2.1% | 1.8% | 1.7% | 1.6% |
| Current ratio | 3.82x | 3.92x | 3.91x | 3.58x | 3.32x | 3.91x | 3.77x | 4.41x | 3.82x | 3.82x |
| Revenue YoY growth | -0.1% | -4.4% | -2.8% | -3.6% | -4.8% | -3.4% | 0.7% | -5.3% | -2.1% | 4.8% |
| Net margin | -5.0% | -8.0% | -7.1% | 17.4% | -271.5% | -4.9% | -197.3% | -5.8% | -2.3% | -0.9% |
| R&D / revenue | 2.2% | 1.8% | 2.0% | 2.4% | 2.8% | 2.0% | 2.2% | 2.4% | 2.2% | 2.1% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | 0.38x | 0.38x | Unavailable | Unavailable | 0.42x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | 17.1% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NEOG in the interactive workspace to inspect any figure back to its filing.
Source filings
10-K · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-09View SEC filing
10-Q · Filed 2026-01-08View SEC filing
10-Q · Filed 2025-10-09View SEC filing
10-K · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-09View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2022-08-31
Operating, investing and financing flows differ from the reported change in cash by 11550000, beyond tolerance 1000000.